Immunotoxin therapy of cancer

被引：417

作者：

Pastan, Ira ^{[1
]}

Hassan, Raffit ^{[1
]}

FitzGerald, David J. ^{[1
]}

Kreitman, Robert J. ^{[1
]}

机构：

[1] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

NATURE REVIEWS CANCER | 2006年 / 6卷 / 07期

关键词：

D O I：

10.1038/nrc1891

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Rationally designed anticancer agents that target cell-surface antigens or receptors represent a promising approach for treating cancer patients. However, antibodies that bind these targets are often, by themselves, non-cytotoxic. By attaching potent toxins we can dramatically improve the clinical utility of some anti-tumour antibodies. Here we describe the construction and clinical utility of several recombinant immunotoxins; each of which is composed of antibody Fv fragments fused to powerful bacterial toxins. Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.

引用

页码：559 / 565

页数：7

共 71 条

[11] Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey [J].

Cohen, KA ;

Liu, TF ;

Cline, JM ;

Wagner, JD ;

Hall, PD ;

Frankel, AE .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (08) :799-806

[12] Influence of immunogenicity on the pharmacokinetics of BMS-191352, a Pseudomonas exotoxin immunoconjugate, in rats and dogs [J].

Damle, B ;

Tay, L ;

Comereski, C ;

Warner, W ;

Kaul, S .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 2000, 52 (06) :671-678

[13] Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma [J].

Dang, NH ;

Hagemeister, FB ;

Pro, B ;

McLaughlin, P ;

Romaguera, JE ;

Jones, D ;

Samuels, B ;

Samaniego, F ;

Younes, A ;

Wang, M ;

Goy, A ;

Rodriguez, MA ;

Walker, PL ;

Arredondo, Y ;

Tong, AT ;

Fayad, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) :4095-4102

[14] Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells [J].

Dannull, J ;

Su, Z ;

Rizzieri, D ;

Yang, BK ;

Coleman, D ;

Yancey, D ;

Zhang, AJ ;

Dahm, P ;

Chao, N ;

Gilboa, E ;

Vieweg, J .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) :3623-3633

[15] Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK®) [J].

Duvic, M ;

Kuzel, T ;

Olsen, EA ;

Martin, AG ;

Foss, FM ;

Kim, YH ;

Heald, PW ;

Bacha, P ;

Nichols, J ;

Liepa, A .

CLINICAL LYMPHOMA, 2002, 2 (04) :222-228

[16] A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma [J].

Engert, A ;

Diehl, V ;

Schnell, R ;

Radszuhn, A ;

Hatwig, MT ;

Drillich, S ;

Schon, G ;

Bohlen, H ;

Tesch, H ;

Hansmann, ML ;

Barth, S ;

Schindler, J ;

Ghetie, V ;

Uhr, J ;

Vitetta, E .

BLOOD, 1997, 89 (02) :403-410

[17]

ENGERT A, 1998, CLIN APPL IMMUNOTOXI, P13

[18] Recombinant immunotoxins for treating cancer [J].

FitzGerald, DJ ;

Kreitman, R ;

Wilson, W ;

Squires, D ;

Pastan, I .

INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 293 (7-8) :577-582

[19] A phase-1 trial of bexarotene and denileukin difftitox in patients with relapsed or refractory cutaneous T-cell lymphoma [J].

Foss, F ;

Demierre, MF ;

DiVenuti, G .

BLOOD, 2005, 106 (02) :454-457

[20]

Foss F M, 2001, Clin Lymphoma, V1, P298, DOI 10.3816/CLM.2001.n.005

← 1 2 3 4 5 6 7 8 →